DISCLAIMER: MediGuard is not intended to be a substitute for professional medical advice. MediGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the MediGuard site and its content is at your own risk. The MediGuard site and the information contained in it is intended for users in the United States and information in other countries may be different.
DHT is a potent agonist of the AR, and is in fact the most potent known endogenous ligand of the receptor. It has an affinity (K d ) of to nM for the human AR, which is about 2- to 3-fold higher than that of testosterone (K d = to nM)  and 15–30 times higher than that of adrenal androgens .  In addition, the dissociation rate of DHT from the AR is 5-fold slower than that of testosterone.  The EC 50 of DHT for activation of the AR is nM, which is about 5-fold stronger than that of testosterone (EC 50 = nM).  In bioassays , DHT has been found to be - to 10-fold more potent than testosterone.